HPB Surgery / 2013 / Article / Tab 3 / Review Article
Selective Interarterial Radiation Therapy (SIRT) in Colorectal Liver Metastases: How Do We Monitor Response? Table 3 Radiological response.
Study Number of patients Extra hepatic disease allowed Chemotherapy treatment Radiologic staging method Time to restaging CT (months) Time to restaging PET (months) Staging criteria Complete response % Partial response % Stable disease % Curative treatment % Median survival (months) Median survival From radioembolisation (months) Anderson et al. [21 ] 7 No Pretreatment >1 month since last course CT 2 NA OWN 0 0 86 NR NR 11 Andrews et al. [34 ] 17 No Pretreatment with 5FU or HAC FUDR CT 4 NA WHO 0 29 29 NR NR 13.8 Gray et al. [30 ] 36 No Concurrent HAC FUDR Nonprotocol also received CT 3* NA WHO 6 44 28 NR NR 17.0 Wong et al. [16 ] 8 Yes Pretreatment with 5FU, LV, and Irinotecan CT PET 3 3 WHO CT 11 PET 58 CT 16 PET 37 CT 16 PET 5 NR NR NR Lim et al. [3 ] 32 Yes# Concurrent 5FU CT 2 NA RECIST 0 31 28 NR NR NR Murthy et al. [29 ] 9 Yes Variable pretreatment regimes CT MR PET NR NR RECIST 0 0 56 NR 24.6 4.5 Lewandowski et al. [35 ] 27 No Pretreatment with capecitabine, 5FU, LV, irinotecan, or oxaliplatin CT PET 3 3 WHO 0 CT 35 PET 83 CT 52 NR NR 9.3 Mancini et al. [36 ] 35 NR Pretreatment based on oxaliplatinor irinotecan CT 1.5 NA RECIST 0 12.5 75 NR NR NR Kennedy et al. [24 ] 208 Yes# Pretreatment based on oxaliplatinor irinotecan CT PET 3 3 WHO 0 35 55 NR NR 10.5 Stubbs et al. [22 ] 100 Yes Concurrent HAC 5FU CT 3 NA OWN 1 73 20 NR 16.2 11 Boppudi et al. [23 ] 54 No+ Concurrent HAC 5FU CT 3 NA OWN WHO 9.3 1.9 76 14.8 NR NR NR 14.1 Jakobs et al. [37 ] 18 No+ NR CT 2–4 NA RECIST 0 76% any response NR NR NR NR Sharma et al. [5 ] 20 Yes Concurrent Folfox4 CT 3 NA RECIST 0 90 10 10% (resection) NR 9.3 van Hazel et al. [38 ] 23 Yes# Concurrent Irinotecan CT 3 NA RECIST 0 48 39 13 12.2 NR Hoffmann et al. [6 ] 21 No Variable pretreatment regimes CT 3 NA RECIST 0 NR NR 5% (RFA) NR NR Cosimelli et al. [15 ] 50 Yes★ Pretreatment based on oxaliplatinor irinotecan CT 1.5 NA RECIST 2 22 24 4% (resection) NM 12.6 Chua et al. [33 ] 140
Yes◯ NR CT 6 NA RECIST 1 31 31 NR 9 NR Nace et al. [31 ] 51 Yes# Prior treatment with various regimes CT PET 3 3 RECIST 0 13 64 10.2 Kosmider et al. [32 ] 19
Yes⊛ FOLFOX or 5FU CT 2 NA RECIST 11 74 5 5% disease free at 6 years 29.4 10.4
NA: not applicable, NR: not recorded, HAC: hepatic artery chemotherapy, FUDR: floxuridine, 5FU: 5-fluorouracil, LV: leucovorin, FOLFOX: 5-fluorouracil, leucovorin, oxaliplatin, FOLFOX4: oxaliplatin cycle 4–12, fluorouracil, leucovorin.
*Limited by government funding, # if liver dominant site of disease, + if present counted as relative contraindication, ★ limited allowed: ≤3 nodules in the same extra hepatic organ each, nodule <3 mm as assessed by a 64 slice ct [15 ], ◯ limitedextrahepatic metastases at on site such as a solitary pulmonary metastases,⊛ limitedpulmonary nodules or abdominal lymphadenopathy.